Tandem Diabetes Care, Inc. (TNDM) - What Are Researchers Thinking About This Stock?

Key Points

• Analyst sentiment is neutral: Twenty-three firms give Tandem Diabetes Care an average “Hold” rating, with a consensus 12-month price target of $27.18. Ratings include nine Buys, twelve Holds, one Sell, and one Strong Buy.
• Recent financial results were mixed: Tandem reported quarterly revenue of $254.56 million, up 5.8% year over year, and an adjusted loss of $0.31 per share that slightly beat estimates. However, the company remains unprofitable, with a negative net margin and analysts expecting a full-year loss.
• Institutional interest increased: First Light Asset Management raised its stake by 157.4%, while several other investment firms initiated new positions during the second quarter.

Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Get Free Report) have received an average rating of "Hold" from the twenty-three research firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, twelve have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $27.18.

A number of equities analysts recently weighed in on the stock. Barclays upgraded shares of Tandem Diabetes Care to a "hold" rating in a research report on Wednesday, October 7th. UBS Group started coverage on shares of Tandem Diabetes Care in a report on Tuesday, July 28th. They issued a "neutral" rating and a $18.00 price target on the stock. William Blair assumed coverage on shares of Tandem Diabetes Care in a report on Friday, August 21st. They issued an "outperform" rating on the stock. Oppenheimer reiterated an "outperform" rating on shares of Tandem Diabetes Care in a research note on Friday, August 7th. Finally, Citigroup decreased their price target on shares of Tandem Diabetes Care from $24.00 to $20.00 and set a "neutral" rating on the stock in a research note on Wednesday, September 30th.

Tandem Diabetes Care Trading Up 2.1%

TNDM stock opened at $16.45 on Tuesday. Tandem Diabetes Care has a 1-year low of $12.26 and a 1-year high of $29.65. The company has a debt-to-equity ratio of 4.62, a current ratio of 3.18 and a quick ratio of 2.65. The company has a market capitalization of $1.14 billion, a price-to-earnings ratio of -17.69 and a beta of 1.66. The business has a 50 day simple moving average of $19.27 and a two-hundred day simple moving average of $18.07.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The medical device company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.32) by $0.01. Tandem Diabetes Care had a negative net margin of 6.08% and a negative return on equity of 45.97%. The business had revenue of $254.56 million during the quarter, compared to analyst estimates of $254.99 million. During the same period last year, the firm posted ($0.78) EPS. The company's revenue was up 5.8% on a year-over-year basis. Research analysts anticipate that Tandem Diabetes Care will post -0.66 EPS for the current fiscal year.

Institutional Investors Weigh In On Tandem Diabetes Care

Several large investors have recently made changes to their positions in TNDM. First Light Asset Management LLC boosted its stake in Tandem Diabetes Care by 157.4% during the second quarter. First Light Asset Management LLC now owns 3,383,553 shares of the medical device company's stock valued at $51,058,000 after buying an additional 2,068,838 shares during the last quarter. Engineers Gate Manager LP bought a new stake in Tandem Diabetes Care in the 2nd quarter worth approximately $976,000. Integrated Wealth Concepts LLC bought a new stake in Tandem Diabetes Care in the 2nd quarter worth approximately $33,000. Squarepoint Ops LLC bought a new stake in Tandem Diabetes Care in the 2nd quarter worth approximately $3,280,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Tandem Diabetes Care in the 2nd quarter worth approximately $395,000.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc is a medical device company focused on developing and commercializing advanced insulin delivery systems for people with diabetes. The company's products are designed to work with continuous glucose monitoring (CGM) systems and digital health tools to help automate and personalize insulin therapy.

Tandem's product portfolio includes the t:slim X2 insulin pump, which features a rechargeable design and software that supports automated insulin delivery. The company also offers the t:slim X2 pump with Control-IQ technology, an algorithm designed to adjust insulin delivery based on CGM readings, and the compact Tandem Mobi pump.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.